Gemcitabine in combination with oxaliplatin as second-line therapy of advanced and metastatic NSCLC
Abstract only 18157 Background: Single agent gemcitabine is active as second line therapy in NSCLC. Oxaliplatin may be non-cross resistant with the other platinum-containing agents used as first-line therapy in NSCLC. The combination of gemcitabine and oxaliplatin (GEMOX) is synergistic in pre-clini...
Saved in:
Published in | Journal of clinical oncology Vol. 25; no. 18_suppl; p. 18157 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
20.06.2007
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract only
18157
Background: Single agent gemcitabine is active as second line therapy in NSCLC. Oxaliplatin may be non-cross resistant with the other platinum-containing agents used as first-line therapy in NSCLC. The combination of gemcitabine and oxaliplatin (GEMOX) is synergistic in pre-clinical models. Methods: A phase II, non-randomized trial was designed to assess the efficacy and tolerability of gemcitabine 1,000 mg/m
2
over 100 min in combination with oxaliplatin 100 mg/m2 over 2 hours both given on days 1 and 15 of each 28-day cycle. Patients with NSCLC were eligible if they had progressed after first line treatment. Primary endpoint was tumor response rate. Planned sample size is 30 patients over a period of 2 years. Functional Assessment of Cancer Therapy- Lung (FACT-L) v.4 questionaire was used to assess quality of life of patients on therapy. Results: Twenty-two patients have been enrolled. 13 males (59%) and 9 females (41%). 15 Hispanic (68%), 4 Caucasian (18%), and 3 African-American (13%). Median age is 55 yrs. Histologic subtypes are as follows: adenocarcinoma, 12; NSCLC not otherwise specified 7; squamous cell carcinoma, 3. Nine patients had an ECOG performance status (PS) of 0 (41%) and 13 had a PS of 1 (59%). Two patients were never smokers. A total of 56 cycles have been administered (median 2, range 1 to 6). GEMOX as second-line therapy was given to 18 patients (81%), third-line to 4 patients (18%). Two patients died on study from disease progression leading to respiratory and multi-organ failure. The following Grade 3 and 4 adverse events were seen in 2 patients each: fatigue, dyspnea, anemia, and multi-organ failure. Cancer pain was seen in 1 patient. Twenty patients are available for assessment of response. Two patients had a confirmed partial response (10%) and another eight had stable disease (40%). Preliminary results of FACT-L analysis in 19 pts shows improvement in Lung Cancer Subscale (LCS) score in 25% of the patients after 2 cycles of therapy. Conclusions: Combination gemcitabine and oxaliplatin is active and well tolerated as second line treatment for NSCLC. Improvement of LCS score after 2 cycles suggests a clinical benefit that is beyond the observed response rate of 10%.
No significant financial relationships to disclose. |
---|---|
AbstractList | Abstract only
18157
Background: Single agent gemcitabine is active as second line therapy in NSCLC. Oxaliplatin may be non-cross resistant with the other platinum-containing agents used as first-line therapy in NSCLC. The combination of gemcitabine and oxaliplatin (GEMOX) is synergistic in pre-clinical models. Methods: A phase II, non-randomized trial was designed to assess the efficacy and tolerability of gemcitabine 1,000 mg/m
2
over 100 min in combination with oxaliplatin 100 mg/m2 over 2 hours both given on days 1 and 15 of each 28-day cycle. Patients with NSCLC were eligible if they had progressed after first line treatment. Primary endpoint was tumor response rate. Planned sample size is 30 patients over a period of 2 years. Functional Assessment of Cancer Therapy- Lung (FACT-L) v.4 questionaire was used to assess quality of life of patients on therapy. Results: Twenty-two patients have been enrolled. 13 males (59%) and 9 females (41%). 15 Hispanic (68%), 4 Caucasian (18%), and 3 African-American (13%). Median age is 55 yrs. Histologic subtypes are as follows: adenocarcinoma, 12; NSCLC not otherwise specified 7; squamous cell carcinoma, 3. Nine patients had an ECOG performance status (PS) of 0 (41%) and 13 had a PS of 1 (59%). Two patients were never smokers. A total of 56 cycles have been administered (median 2, range 1 to 6). GEMOX as second-line therapy was given to 18 patients (81%), third-line to 4 patients (18%). Two patients died on study from disease progression leading to respiratory and multi-organ failure. The following Grade 3 and 4 adverse events were seen in 2 patients each: fatigue, dyspnea, anemia, and multi-organ failure. Cancer pain was seen in 1 patient. Twenty patients are available for assessment of response. Two patients had a confirmed partial response (10%) and another eight had stable disease (40%). Preliminary results of FACT-L analysis in 19 pts shows improvement in Lung Cancer Subscale (LCS) score in 25% of the patients after 2 cycles of therapy. Conclusions: Combination gemcitabine and oxaliplatin is active and well tolerated as second line treatment for NSCLC. Improvement of LCS score after 2 cycles suggests a clinical benefit that is beyond the observed response rate of 10%.
No significant financial relationships to disclose. |
Author | Alencar, A. J. Walker, G. Blaya, M. Macintyre, J. Flores, A. Lopes, G. Rocha-Lima, C. Raez, L. Farfan, N. |
Author_xml | – sequence: 1 givenname: A. J. surname: Alencar fullname: Alencar, A. J. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 2 givenname: M. surname: Blaya fullname: Blaya, M. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 3 givenname: L. surname: Raez fullname: Raez, L. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 4 givenname: N. surname: Farfan fullname: Farfan, N. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 5 givenname: G. surname: Lopes fullname: Lopes, G. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 6 givenname: G. surname: Walker fullname: Walker, G. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 7 givenname: A. surname: Flores fullname: Flores, A. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 8 givenname: J. surname: Macintyre fullname: Macintyre, J. organization: U Miami Jackson Mem Hosp, Miami, FL – sequence: 9 givenname: C. surname: Rocha-Lima fullname: Rocha-Lima, C. organization: U Miami Jackson Mem Hosp, Miami, FL |
BookMark | eNo10MtOwzAQBVALFYm28A8W-wQ_4tplhyIoSBUsAImdNXEmqqvEjuLw6N-T8ljdq9HMLM6CzEIMSMglZzkXjF3tXcyn1LlQOTc2vfd9OxWu9AmZcyV0prVSMzJnWoqMG_l2RhYp7RnjhZFqTtwGO-dHqHxA6gN1sZsqjD4G-unHHY1f0Pq-nSaBQqIJXQx11h7Xxx0O0B9obCjUHxAc1hRCTTscIY3ThaOPz-W2PCenDbQJL_5ySV7vbl_K-2z7tHkob7aZ48zorFECkFeVY043aynrAhlbF86sKmyMllxxVUMttShQS1ZUoIr1yuiVkQ4qiXJJrn__uiGmNGBj-8F3MBwsZ_bIZScue-SyQtl_LvvDJb8Bei9krQ |
CitedBy_id | crossref_primary_10_1097_JTO_0b013e3181ffe8ef |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/jco.2007.25.18_suppl.18157 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 18157 |
ExternalDocumentID | 10_1200_jco_2007_25_18_suppl_18157 |
GroupedDBID | --- .55 .GJ 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 8WZ A6W AARDX AAWTL AAYEP AAYOK AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY |
ID | FETCH-LOGICAL-c1087-f52ae1bbc0c7f933d4e0094c86bef8731515dad3724e7304ba549687683cab3e3 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 03:50:06 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 18_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1087-f52ae1bbc0c7f933d4e0094c86bef8731515dad3724e7304ba549687683cab3e3 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1200_jco_2007_25_18_suppl_18157 |
PublicationCentury | 2000 |
PublicationDate | 2007-06-20 |
PublicationDateYYYYMMDD | 2007-06-20 |
PublicationDate_xml | – month: 06 year: 2007 text: 2007-06-20 day: 20 |
PublicationDecade | 2000 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2007 |
SSID | ssj0014835 |
Score | 1.8962854 |
Snippet | Abstract only
18157
Background: Single agent gemcitabine is active as second line therapy in NSCLC. Oxaliplatin may be non-cross resistant with the other... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 18157 |
Title | Gemcitabine in combination with oxaliplatin as second-line therapy of advanced and metastatic NSCLC |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvCAaIb_kB7WVLSGwndh6rwRiDThN0Ut8i27GlTiyZ1k6i_EX8mZzjJHUZCNhLlFrt9eN-uvvd9T4Qep3KRIBtpJEtWAYBimWRzHUaWaHT3JqEW-ManCfH-eEpO5pls9HoR1C1dLVUsf7-276Sm2gVzkCvrkv2PzQ7CIUDuAf9whU0DNd_0vF7c64htldzP_oD3gJuvUbb_GrzDVj2hat2q90-mYULfquoJZa-72q1UQbgcujnZildk9Fc7x5_2e82Cl8nr0NDZVPrjcT82DUx-aLtcbx7FA_h_le5annqZDj6LH32-tNwciAvrewawDbSEW3tHEkCq8UpicBOzLyD6awq4UDj_Tze3uz6fuceXqJcuC2mgSkF6uFHV3d-eXh8zeiTdp_1mW78REqSxb24OBASTtr-xQMOdYkuIgIZJchy-zl5SbKyl1W2sm6h24QXmSseffvh4_B_FRN-lWv_5bvxtiDjzZ8_V0CFAk4zvY_udfrEY4-sB2hk6m10Z9KVW2yjnRM_2Hy1h6frPr3FHt7BJ-uR56uHSAdIxPMaB0jEDok4QCKWCxwgEXdIxI3FPRIxIBGvkYhbJD5CpwfvpvuHUbe-I9JpAq7LZkSaVCmdaG4LSitmXB2rFrkyVnDqqHQlK8oJM-BnmJIZK3LwzoJqqaihj9FW3dTmCcKMVjbXTFXW5kwU8DSugHux1GSVsGn-FNH-lywv_JSW8u-6fHajVz1Hd9e4f4G2lpdX5iUQ06V61WLiJ0yQjQA |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gemcitabine+in+combination+with+oxaliplatin+as+second-line+therapy+of+advanced+and+metastatic+NSCLC&rft.jtitle=Journal+of+clinical+oncology&rft.au=Alencar%2C+A.+J.&rft.au=Blaya%2C+M.&rft.au=Raez%2C+L.&rft.au=Farfan%2C+N.&rft.date=2007-06-20&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=25&rft.issue=18_suppl&rft.spage=18157&rft.epage=18157&rft_id=info:doi/10.1200%2Fjco.2007.25.18_suppl.18157&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_jco_2007_25_18_suppl_18157 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |